Mackenzie Financial Corp Has $12.54 Million Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Mackenzie Financial Corp boosted its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 26.9% in the fourth quarter, HoldingsChannel reports. The firm owned 1,562,694 shares of the company’s stock after acquiring an additional 331,462 shares during the period. Mackenzie Financial Corp’s holdings in Bausch Health Companies were worth $12,543,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Goldentree Asset Management LP increased its stake in shares of Bausch Health Companies by 19.6% in the third quarter. Goldentree Asset Management LP now owns 23,987,462 shares of the company’s stock valued at $197,177,000 after buying an additional 3,931,234 shares in the last quarter. Nomura Holdings Inc. increased its position in Bausch Health Companies by 67.7% in the 3rd quarter. Nomura Holdings Inc. now owns 18,086,000 shares of the company’s stock valued at $148,667,000 after acquiring an additional 7,303,015 shares in the last quarter. Hudson Bay Capital Management LP raised its stake in shares of Bausch Health Companies by 35.3% in the third quarter. Hudson Bay Capital Management LP now owns 11,500,000 shares of the company’s stock worth $94,530,000 after acquiring an additional 3,000,000 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Bausch Health Companies by 1.6% during the third quarter. Vanguard Group Inc. now owns 11,487,768 shares of the company’s stock worth $94,429,000 after purchasing an additional 175,489 shares in the last quarter. Finally, Mizuho Markets Americas LLC bought a new stake in shares of Bausch Health Companies during the third quarter valued at approximately $57,540,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

BHC opened at $8.69 on Friday. The company has a fifty day moving average price of $9.29 and a two-hundred day moving average price of $8.15. The firm has a market capitalization of $3.18 billion, a PE ratio of -5.36 and a beta of 0.85. Bausch Health Companies Inc. has a 52 week low of $5.57 and a 52 week high of $11.46.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.14. The business had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The firm’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.02 earnings per share. Equities analysts forecast that Bausch Health Companies Inc. will post 3.95 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on BHC. Jefferies Financial Group reduced their price objective on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $12.00 price target on shares of Bausch Health Companies in a research note on Friday, April 12th. Finally, StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.